Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29170246 | 1.00 | NR1H2 (0.47) | NR1H2NAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL26636891 | 1.00 | NR1H2 (0.47) | NR1H2NAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL10220897 | 1.00 | NR1H2 (0.47) | NR1H2NAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL30115827 | 0.91 | NR1H2 (0.49) | NR1H2NAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL30390162 | 0.88 | NR1H2 (0.40) | NR1H2NAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL13744392 | 0.85 | NR1H2 (0.44) | NR1H2NAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL30199567 | 0.85 | NR1H2 (0.44) | NR1H2NAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL30338313 | 0.84 | NR1H2 (0.49) | NR1H2NAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL30778455 | 0.84 | NR1H2 (0.49) | NR1H2NAMPTUSP2SMN1; SMN2GPR119 | |
| SCHEMBL3315088 | 0.81 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2GPR119EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221998-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-07-10 | — | — | US | disclosed |
| EP-4504730-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | Dana-Farber Cancer Institute, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119365454-A | Discovery of covalent EGFR inhibitors through cysteine 775 | 丹娜-法伯癌症研究院 | 2025-01-24 | — | — | CN | disclosed |
| CN-117715903-A | Cereblon binding compounds, compositions thereof, and methods for their use in therapy | 新基公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023196409-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | NR1H2 9/4885NAMPT 1943/4885USP2 4635/4885 |
| US-20250221998-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | EGFR, ERBB2, ERBB3 | NR1H2 2416/4885NAMPT 3166/4885USP2 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.